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Epidemiology of Japanese Encephalitis
(JE) in South Korea
Historically, JE occurred seasonally in South
Korea, causing high rates of illness and death.
Although public health records concerning the
incidence of the disease before 1933 are not
available, outbreaks of “summer encephalitis”
were recognized. During summer 1934-35, an
outbreak was reported of suspected encephalitis,
with acute onset of spiking fever and headache,
as well as neurologic abnormalities and mental
changes. Although these outbreaks were
described as meningococcal meningitis by
Korean health authorities, some Japanese
workers reported that many of the cases were
encephalitis (1,2). In 1946, Sabin et al. (3)
isolated JE virus from an American soldier
stationed in South Korea. Deuel et al. (4)
conducted the first extensive serologic survey  by
neutralizing test in four areas of South Korea
and reported that JE virus was widely
disseminated. In 1947, JE was added to the list of
first-class emergency diseases in South Korea.
In 1949, when JE became notifiable, 5,548
cases of clinically suspected disease were reported
with 2,429 deaths (49% case-fatality rate). The
criteria for reporting were high spiking fever,
headache, and mental changes with any
symptom of central nervous system involvement.
Hullinghorst et al. (1), who  described the 1949
epidemic in South Korea, reviewed >600 hospital
records. Results of bacterial cultures of
cerebrospinal fluid (CSF) were reviewed for 567
cases, and the complement fixation and
neutralization tests were performed in selected
cases. Pathology findings and JE virus isolation
from a case, negative results of CSF bacterial
cultures, and a relatively uniform clinical
picture, including acute high fever, headache,
and various neurologic abnormalities, suggested
that the outbreak in 1949 was JE (1,5).
Thereafter, several outbreaks of thousands of JE
cases were reported every 2 to 3 years, and JE
was recognized as a recurring public health
problem in South Korea (6,7).
In 1954, when the Communicable Disease
Control Act (Reg. 308) was enacted, JE was
classified as a first-class notifiable communicable
disease. The largest recorded JE epidemic,
involving  6,897 reported cases, occurred in 1958
(7). In 1963, JE was reclassified as a second-class
notifiable disease, along with polio, pertussis,
measles, mumps, and other childhood diseases.
Since 1964, seroepidemiologic studies with the
hemagglutination inhibition test (HI) have been
conducted routinely for clinically suspected
cases. In 1964, 108 paired and 1,636 acute-phase
sera were tested (8). The results indicated that
86.7% of acute-phase sera were negative by the
HI test and 54% of paired sera were positive in
their second sample. Several thousand cases
were reported annually until 1968, with the
exception of 1963, when only 19 cases were
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 Japanese encephalitis (JE), once a major public health problem in South Korea,
has declined since the 1980s, as a result of improved living conditions, a mosquito
eradication program, and a national JE vaccination program, which includes annual
booster vaccine for all children  < 15 years of age. Increased immunity has greatly
reduced illness and death; however, vaccine adverse effects are increasing, and a
National Compensation Program for Vaccine Injury was begun in 1995. This article
reviews past successes, current problems, and future direction of the JE vaccination
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Figure 1. Cases of Japanese encephalitis by liters of
vaccine distributed, 1936–1998, South Korea.
Figure 2. A. Incidence of Japanese encephalitis (JE)
per 100,000, by province, South Korea, 1949 and
1958  (7). B. Incidence of JE per 100,000, by province,
South Korea, 1965–98 (modified from 8-11,24).
A
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reported; Chang et al. (9) provide evidence for
underreporting in that year (Figure 1). Case
reports sharply declined to <100 cases in 1969;
<1,000 cases were reported annually until 1973.
The last large epidemic was recorded in 1982,
when 1,197 cases and 40 deaths were reported.
This rapid decline in reported cases may be
related to the extensive use of insecticides in rice
farming, which led to a marked decrease of Culex
tritaeniorhynchus in rural habitats (10,11).
The highest incidence of JE was recorded in
Seoul and Kyonggi Province during the first
officially reported outbreak in 1949 (Figure 2A).
In the epidemics during 1965 to 1984, a higher
incidence was recorded in the southwestern than
in the northeastern provinces (Figure 2B). The
southwestern provinces are mainly under rice
cultivation with large flooded rice paddies, while
the northeastern provinces are mountainous.
Vector mosquito populations were more preva-
lent in the southwest than in the northeast (8),
leading to greater risk for enzootic viral
transmission in the southwestern provinces. The
high incidence in Seoul in the 1949 outbreak may
be accounted for by the rapidly increasing
susceptible population in the capital and its
suburbs since 1945 (7). Approximately 90% of the
cases occurred from mid-August to mid-
September; more than 80% were among children
3 to 15 years of age (9,10).
Factors affecting the size of JE epidemics
include the risk for being infected by the virus
when bitten by a vector mosquito and the JE
seropositive rate in the population. In 1965,
before the national vaccination program was
implemented, Chang et al. (9) estimated the
natural seroconversion rate of HI antibody in
children <15 years of age at approximately 9%,
indicating that the estimated incidence of JE
cases during epidemics would have been higher
without intervention. Several studies comparing
seroprevalence rates before and after the
epidemic season indicated that the seropositivity
rate was higher in South Choongchung Province
(86.4% before the epidemic season vs ~100% after19 19 19 19 19 Vol. 6, No. 1, January–February 2000 Emerging Infectious Diseases
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Figure 3. Seropositivity of HI antibody before and
after the Japanese encephalitis epidemic. (A), (B), (C)
before the implementation of vaccination program;
(D), (E) after the implementation of vaccination
program (modified from 13-16).
Table 1. The Japanese encephalitis (JE) epidemic
forecast program, South Korea
Date
index
case
 Date of Date of diag-
Year attention  alarm nosed    Provincea
1975 6/24 8/19 8/22 South Cholla
1976 6/25 8/18 9/10 South Cholla
1977 6/20 8/ 9 8/18 Cheju
1978 6/23 8/16 8/22 South Cholla
1979 6/20 8/ 7 8/30 South Cholla
1980 6/16 8/22 8/28 South Cholla
1981 6/26 8/19 8/22 Kyonggi
1982 6/14 7/23 8/ 6 South Cholla
1983 5/24 8/16 8/23 South Cholla
1984 6/5 8/16    - NAb
1985 5/21 8/20    - NA
1986 5/22 8/25    - NA
1987 5/21 7/30 8/11 South Cholla
1988 5/30 8/10 9/8 South Cholla
1989 5/25 8/25    - South Cholla
1990 5/23 8/21 9/26 South Cholla
1991 5/23 7/31 7/29 Kyonggi
1992 5/13 8/13 8/24 South Cholla
1993 6/1 8/10 8/12 Cheju
1994 5/20 8/4 9/6 South Cholla
1995 5/11 8/24    - South Cholla
1996 5/23 8/13 South Cholla
1997 5/27 6/20 Kyonggi
1998 5/7 8/13 8/6 South Cholla
aProvince is the place where JE virus was first isolated in that
year.
bNot available.
the epidemic season in 1984) than in Seoul (56%
before the epidemic season vs ~72% after the
epidemic season in 1987) (Figure 3) (12-15).
From 1985 to 1998, only 21 cases of JE were
serologically confirmed. Factors leading to this
decrease include the National Immunization
Program (NIP), initiated in 1983, which has
conferred protective immunity on children at
risk. The national socioeconomic growth for the
past 3 decades has allowed improved standards
of living and environmental conditions. The
modernization of agricultural practices led to
changes in the epidemiology of JE.
Epidemic Forecast Program
Since 1975, an epidemic forecast program to
alert the public against JE has been imple-
mented by the health authorities every year
before the epidemic season (16) (Table 1). To
predict the possibility of an outbreak, the health
authorities have attempted to isolate the virus
from the vector mosquito, C. tritaeniorhynchus;
estimate population density of C. tritaeniorhynchus
among captured mosquitoes; and determine JE
antibody levels in pigs. Monitoring for
C. tritaeniorhynchus begins in early May. The
population density of C. tritaeniorhynchus in
mosquitos captured in seven urban and rural
areas was 76.1% in 1982, when the most recent
epidemic occurred (11). Because outbreaks in
humans seem closely related to a rapid rise of HI
antibody titers in pigs, the blood of young pigs
(<6 months old) is screened weekly at
slaughterhouses for immunoglobulin (Ig) M
antibody. In areas where epidemics have
occurred, vector mosquitos collected are homog-
enized and injected into suckling mice; JE virus
is identified by HI and, recently, by polymerase
chain reaction in the brains of mice manifesting
JE symptoms.
When the JE vector mosquito is first detected,
health authorities issue an alert that encourages
JE vaccination (Table 1). If JE IgM antibody
titers increase in pigs or JE virus is isolated,
aggressive mosquito control is implemented.
Active JE Immunization in the Spring
Mass Immunization Campaign
A small amount of the mouse brain-derived
formalin-inactivated Nakayama vaccine from
Japan was imported in 1967 (17,18). In the early20 20 20 20 20 Emerging Infectious Diseases Vol. 6, No. 1, January–February 2000
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1970s, the Nakayama vaccine began to be
produced locally. Despite an active campaign
with the Nakayama vaccine, the annual number
of doses distributed remained under 500,000 in
the 1970s, for a vaccine coverage rate of <5% (11).
However, the vaccine coverage rate increased to
16.8% in 1981. The most recent epidemics—
1,197 reported cases in 1982 and 139 in 1983—
prompted a mass immunization program for
children at risk. Children 3 to 15 years of age
were vaccinated at state public health centers,
and simultaneous vaccination in the private
sector was encouraged; as a result, the
immunization rate increased to 60% in 1983,
when a JE epidemic occurred. In 1986, 12 million
doses were distributed in the public and private
sectors, which was more than the estimated
number of children <15 years of age. From 1985
to 1992, almost 10 million doses of Nakayama
vaccine were distributed each year, enough to
vaccinate 97% of the nation’s children (Figure 1).
In 1983, the age of initial dose of JE vaccine
was recommended by the health authorities at 3
years of age, except for areas in which the
disease had recently become endemic, where it
could be given earlier. The series consisted of
three doses of primary vaccination, with
annual boosters until 15 years of age. Because
the vaccination rate could not be maintained
above 90% by individual immunization during
the spring campaign (May to July), mass
immunization at schools and public health
centers was used.
Since 1984, when JE vaccine coverage
reached almost 90%, only a few sporadic cases
occurred in young adults or the elderly. The
incidence of JE was reduced from >18.5/105 in
1964 to <0.02/105 over the past 3 decades.
Several factors contributed to the rapid decline.
In addition to improved living conditions, public
health, the widespread use of agricultural
herbicides and insecticides, a decrease in the
population density of vector mosquitos by the
removal of mosquito habitats, and the
modernization of agricultural practices, such
as improved sanitary conditions on pig farms in
rural areas, may have decreased the risk for
human infection. In South Korea,
C. tritaeniorhyncus usually appears in May and
multiplies rapidly in July and August. From
1982 to 1985, mosquitos were collected in seven
areas from May to late October. The number of
mosquitos gradually decreased, from 11,278 per
day (76% C. tritaeniorhyncus) in 1982; to 4,334
(59.2%) in 1983; 2,150 (40.3%) in 1984; and 1,212
(34.4%) in 1985 (11). The virus infestation rate of
the vector mosquito has been consistently <1%
since 1990. Consequently, the risk of being
exposed to the vector mosquito and infected by
JE virus has decreased.
Another contributing factor is the policy of
maintaining high levels of immunity through the
expansion of the routine childhood immuniza-
tion program. An immunization coverage rate
>97% has significantly contributed to the
prevention of JE. In 1969, a JE vaccine efficacy
trial was performed among schoolchildren in
southwestern provinces in South Korea; ap-
proximately 45,000 children were vaccinated
and another 45,000 were controls. Although no
epidemic occurred during this period (19,20)
because of vaccination, the HI seropositive rate
of 11.6% in prevaccination sera increased to 75%
in postvaccination sera after two doses of mouse
brain-derived Nakayama vaccine. The seroposi-
tivity rate by neutralizing antibody test was 99%
postvaccination.
At present, visitors to South Korea on
business or vacation  are considered at low risk
for JE; routine vaccination with Nakayama
vaccine may not be necessary for these travelers.
However, JE immunization is recommended for
visitors to disease-endemic areas during
transmission season. Vaccine is advised
especially for travelers who stay for an
extended time (>30 days) or are at high risk for
exposure to vector mosquitos through activi-
ties or housing.
Vaccine Manufacture and Supply
In 1972, the manufacture of Nakayama JE
vaccine was privatized and transferred to the
South Korea Green Cross Company. Currently,
seven pharmaceutical companies manufacture
JE vaccine. Before 1995, when boosters were
given annually, the total amount of vaccine
needed for the population at risk was 8,500 to
9,000 liters per year. Vaccine production is
projected more than 1 year in advance; the
amount to be used the next year is usually
determined in February. Then the injection of JE
virus into mice, recovery of the virus from mouse
brain tissue, and production of bulk vaccine
begin. Vaccine is ready in October, and after a
thorough testing in January of the following
year, is distributed in March.21 21 21 21 21 Vol. 6, No. 1, January–February 2000 Emerging Infectious Diseases
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Vaccine Adverse Effects
Although the mass immunization campaign
was successful in attaining high rates of
vaccination coverage, JE vaccine-related
adverse effects may have been overlooked. A
reporting system was not available until 1995,
so the incidence of JE vaccine-related adverse
effects among South Korean children is not
known. However, in 1994, six cases of severe
systemic illness after JE vaccination were
reported (21) (Table 2). Two sudden deaths were
attributed to anaphylactic reaction to the
vaccine, and four cases of severe neurologic
illness, including encephalopathy and acute
disseminated encephalomyelitis, were reported.
Since 1994, seven cases have been filed with
the Advisory Committee of the National
Immunization Program, according to the
National Compensation Program for Vaccine
Injury (Table 2).
Table 2. Cases of adverse reactions to Japanese encephalitis vaccine reported to the National Compensation
Program for Vaccine Injury, South Korea, 1994
Date of Symptoms at
Age/ Previous Vaccine vacci-   Date of onset/ sequelae/
Case sex vaccination strain nation onset laboratory findings Outcome
1 5/F 2 doses of JE Nakayama 5/23/94 5/23/94 Anaphylactic shock Death
(Lot 3008)   collapse, cardiac arrest
2 5/M 2 doses of JE Nakayama 5/23/94 5/23/94 Anaphylactic shock Death
(Lot 3008)   collapse, cardiac arrest
3 15/F 8 doses of JE Nakayama 4/4/94
(Unknown)
2 doses of Hantavax 4/20/94 5/13/94 Headache, auditory Death
  HRFS (Unknown)   hallucination, seizure
Brain CT normal
MRI normal
EEG moderate to severe cortical
  dysfunction, multifocal
  generalized polyspike and
  slow wave on both hemispheres
CSF protein (20 mg/dl), glucose
  (78 mg/dl), WBC (17/mm3)
4 8/F >2 doses of JE Nakayama 5/7/94 5/19/94 High fever, seizure Recovery
(Lot 0132-93011) Brain CT normal
EEG  compatible with
  encephalopathy
CSF protein (82 mg/dl), glucose
  (99 mg/dl), WBC (18/mm3)
5 9/F >3 doses of JE Nakayama 4/24/94 5/11/94 High fever, headache, Death
(Unknown)   vomiting, seizure
Brain CT diffuse brain edema
CSF protein (6 mg/dl), glucose
  (75 mg/dl), WBC (10/mm3)
6 2/F none Nakayama 4/11/94 4/23/94 Urinary incontinence, Mental
(Unknown)   drooling, high fever,   retar-
  motor weakness, vomiting,   dation
  cranial nerve palsy (III,IV,VI)
  diplopia and phtosis,
  headache, seizure
MRI compatible with acute
  disseminated encephalomyelitis
7 10/M >3 doses of JE Nakayama 4/23/96 5/25/96 Headache, vomiting, seizure, Death
  coma
JE, Japanese encephalitis; HFRS, Hemorrhagic fever with renal syndrome; CT, computer-assisted tomography; MRI, magnetic
resonance imaging; EEG, electroencephalograph; CSF, cerebrospinal fluid; WBC, white blood cells.22 22 22 22 22 Emerging Infectious Diseases Vol. 6, No. 1, January–February 2000
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Figure 4. A. Plaque-reduction neutralizing antibody
titers (PRNT) according to interval since last booster
injection with Nakayama vaccine among 311 South
Korean children, 1996. B. PRNT antibody seroposi-
tivity rate according to the interval since last booster
injection.
A
B
The Future of the Immunization Program
Although the cost-effectiveness of the JE
immunization program, including annual boost-
ers, has not been evaluated, JE has been
successfully controlled in South Korea for the
past 2 decades. Questions remain about the
optimum immunization schedule, including
appropriate ages for initial vaccination and
boosters. The state health authority recom-
mends two doses 4 weeks apart with a booster 1
year later as a primary immunization, and
annual boosters thereafter up to 15 years of age.
Since the longevity of neutralizing antibody after
primary vaccination was not known and seemed
short lived, frequent boosters appeared neces-
sary. However, without sound evidence, the total
of 14 doses of vaccine until 15 years of age led to
concerns about excessive vaccination and
increased risk for vaccine adverse effects.
The 1994 report of the cluster of severe
adverse systemic effects after JE vaccination
prompted medical and social debate (22,23). A
causal association between JE vaccine and the
cluster of severe adverse effects has not been
clearly established; however, empiric evidence,
including the timing of events, characteristics of
the adverse reactions, susceptibility, and lack of
alternative etiologic agents, indicates a causal
relationship. Public concern over adverse
reactions led to refusal of the vaccination and a
consequent decrease in coverage rate. In
response, the National Compensation Program
for Vaccine Injury was begun in 1995.
During public debate about the JE immuni-
zation schedule, the safety and quality of the
domestically produced JE vaccines were ques-
tioned. The Advisory Committee of the National
Immunization Program announced that the
annual booster immunization schedule had
become impractical because of the inappropriate
administration of the vaccine during the          mass
immunization in the spring, the need to define
the long-term immunity in the elderly (> 65
years of age), poor recognition of adverse effects,
the need to guarantee the quality of the vaccine
manufactured in South Korea, and public
reluctance to receive JE vaccination. The
committee agreed that the JE immunization
program should be improved with regard to the
schedule, age of initial vaccination, booster
schedule, and vaccine strain. The annual booster
schedule was changed to once every 2 years, and
single-dose rather than multidose vials were
used, as recommended by the South Korean
Society of Pediatricians.
In 1996, a seroprevalence study for plaque-
reduction neutralizing antibody (PRNT) was
carried out to indirectly evaluate the efficacy of
booster vaccination in 311 schoolchildren (24).
The neutralizing antibody titers were found to
decrease gradually as the interval between
boosters increased (Figure 4A). The seropositiv-
ity rate of 98.1%, 99%, and 95.6% at 6, 18, and 30
months, respectively, had declined to 71.4% by
42 months (Figure 4B).
To replace the inactivated mouse brain-
derived vaccine, a clinical trial with a live
attenuated SA14-14-2 vaccine, which has been23 23 23 23 23 Vol. 6, No. 1, January–February 2000 Emerging Infectious Diseases
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Figure 5. Primary or booster neutralizing antibody
responses to one dose of Japanese encephalitis SA14-
14-2 vaccine in South Korean children, 1997 (26).
used safely and effectively in >100 million
children in China since 1988 (25), was conducted
in South Korean children in 1997. A preliminary
immunogenicity study among South Korean
children 1 to 3 years of age indicated a 96% rate
of seroconversion in PRNT antibody, with a
geometric mean titer (GMT) of 188 after a single
primary immunization dose. In children who had
been immunized with two or three doses of
inactivated Nakayama vaccine, the booster
administration of SA14-14-2 vaccine produced
an anamnestic response with a GMT of 3,378 in
all cases without virus-specific IgM response
(Figure 5) (26).
During the last 10 years, JE has occurred
more frequently in adults than in children—two-
thirds of Korean JE patients were middle-aged
adults. Adults are not protected by the current
immunization program, probably because of
waning immunity. Long-term immunity must be
maintained to prevent secondary vaccine failure.
A single booster with the live-attenuated SA14-
14-2 vaccine might confer long-term immunity
for adults and decrease the frequency of
vaccination, as well as the risk for vaccine
adverse effects.
The national immunization program against
JE in children should be continued according to
established schedules in South Korea; however,
the booster schedule should be adjusted.
Surveillance for JE and vaccine adverse
reactions should be strengthened to better assess
the number of cases and reactions associated
with immunization. A new, more advanced
vaccine, such as the live attenuated SA14-14-2
vaccine, should be adopted and integrated into
the pediatric immunization schedule.
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